2Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int, 2003, 45(3) :249 - 254.
3Mir T, Stephani S, Eiselt M, et al. Plasma concentration of N-terminal pro-brain natriurtic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics,2002, 110(6):e76- 87.
4Kawai K, Hata K, Takaoka H, et al. Plasma brain natriuretic peptide as a noval therapetic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: a potential of hormone-guided treatment. Am Heart J, 2001, 141(6) :925 - 932.
5Hirata Y, Matsumoto A, Aoyagi T, et al. Measurement of plasma brain natriuretic peptide level as a gudie for cardiac overload. Cardiovasc Res, 2001, 51:585 - 591.
6Kirkwood F, Vandana S, Mihai G, et al. B-Type natriuretic peptide: from bench to bedside. Am Heart J,2003, 145(2) :S34- 46.
7Kinnunen P, Vuolteenaho O, Ruskoaho H, et al. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium:effect of stretching. Endocrinology, 1993, 132(5) :1961- 1970.
8Ikeda T, Matsuda K, Itoh H, et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stressin patients with aortic stenosis. Am Heart J, 1997, 133(3):307- 314.
9Colann SD, Borow KM, Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol, 1984, 4(3) :715- 721.
10Kimball T, Daniels S, Meyer R, et al. Relation of symptoms to contractility and defect size in infants with ventricular septal defect. Am J Cardiol, 1991, 67(3) :1097- 1102.
